InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,346.99
(
-0.11%
)
US TECH 100
18,488.00
(
-0.25%
)
Dow Jones
38,798.99
(
-0.22%
)
Brent Oil
79.40
(
0.00%
)
Bitcoin
69,336.04
(
0.01%
)
Post# of 252107
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119787
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: HobGlobulin post# 63715

Friday, 10/03/2008 1:59:37 AM

Friday, October 03, 2008 1:59:37 AM

Post# of 252107
Roche, DNA to Develop Novel CD20 Compound

GlycArt, a specialist in mAb glycosylation, was acquired by Roche for $180M in 2005.]

http://biz.yahoo.com/bw/081003/20081002006455.html

›Genentech, GlycArt and Roche Enter into Collaboration Agreement for Potential Cancer Therapy

Friday October 3, 1:30 am ET

SCHLIEREN/BASEL, Switzerland & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, Inc. (NYSE: DNA ), GlycArt, a company wholly-owned by Roche, and Roche have entered into a collaboration agreement, including a license from GlycArt to Genentech, for the joint development and commercialization of GlycArt’s GA101 molecule. The companies will be developing GA101, a humanized anti-CD20 monoclonal antibody engineered to increase both direct- and immune-mediated target cell death, for the potential treatment of hematological malignancies and other oncology-related B-cell disorders such as non-Hodgkin’s lymphoma.

Pablo Umaña, Chief Scientific Officer and co-founder of GlycArt, said, “With its unique mode of action, we believe GA101 has the potential to extend the therapeutic benefit over current standards of care, including treatment for patients who do not respond to current therapies.”

“This collaboration with GlycArt and Roche for the GA101 molecule complements our existing research program and our focus on innovative compounds,” said Hal Barron, M.D., Genentech senior vice president, development and chief medical officer. “We are pleased that through this program we may have the potential to offer a new option to treat patients with hematological malignancies.”

“Our early investment in pioneering technologies continues to provide new hope for patients,” said William M. Burns, CEO Roche Pharmaceuticals. “The exciting work in antibody engineering carried out by our scientists at GlycArt can now be taken to the next stage in developing clinically differentiated treatments.”

In association with this agreement, Genentech, Roche and GlycArt will share certain development costs and Genentech will record $105 million in research and development expense in its third quarter 2008 results. Genentech will receive commercialization rights in the United States.

GA101 is currently in Phase I/II clinical trials for CD20-positive B-cell malignancies, such as non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). GlycArt and Roche plan to provide an update on Phase I data for GA101 at the American Society of Hematology meeting in December 2008.‹

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up